Using Chitosan-Stabilized, Hyaluronic Acid-Modified Selenium Nanoparticles to Deliver CD44-Targeted PLK1 siRNAs for Treating Bladder Cancer

References

• Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Eckstein M, Kimmel C, Bruendl J et al. Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer. Sci. Rep. 11(1), 1–9 (2021).
   PubMed Web of Science ®Google Scholar
• Yassaie O, Chehroudi C, Black PC. Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma. Ther. Adv. Med. Oncol. 13, 1–14 (2021).
   Web of Science ®Google Scholar
• Nason GJ, Ajib K, Tan GH, Kulkarni GS. Bladder-sparing treatment options in localized muscle-invasive bladder cancer. Expert Rev. Anticancer Ther. 20(3), 179–188 (2020).
   PubMed Web of Science ®Google Scholar
• Ebbing J, Heckmann RC, Collins JW et al. Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer. Sci. Rep. 8(1), 1–19 (2018).
   PubMedGoogle Scholar
• Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70(5), 404–423 (2020).
   PubMed Web of Science ®Google Scholar
• Shakeel I, Basheer N, Hasan GM, Afzal M, Hassan MI. Polo-like kinase 1 as an emerging drug target: structure, function and therapeutic implications. J. Drug Target. 29(2), 168–184 (2021).
   PubMed Web of Science ®Google Scholar
• Seyedabadi S, Saidijam M, Najafi R et al. Assessment of CEP55, PLK1 and FOXM1 expression in patients with bladder cancer in comparison with healthy individuals. Cancer Invest. 36(8), 407–414 (2018).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Matsuyama H, Kawauchi S et al. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 70(3), 231–237 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang G, Kong C. Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells. J. Cell. Mol. Med. 21(4), 758–767 (2017).
   PubMed Web of Science ®Google Scholar
• Liu Z, Sun Q, Wang X. PLK1, a potential target for cancer therapy. Transl. Oncol. 10(1), 22–32 (2017).
   PubMed Web of Science ®Google Scholar
• Reda M, Ngamcherdtrakul W, Nelson MA et al. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nat. Commun. 13(1), 1–11 (2022).
   PubMed Web of Science ®Google Scholar
• Seth S, Matsui Y, Fosnaugh K et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol. Ther. 19(5), 928–935 (2011).
   PubMed Web of Science ®Google Scholar
• Bidar N, Darroudi M, Ebrahimzadeh A et al. Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: recent advances. Eur. J. Pharmacol. 915, 174639 (2022).
   PubMed Web of Science ®Google Scholar
• Shahidi M, Abazari O, Bakhshi A et al. Multicomponent siRNA/miRNA-loaded modified mesoporous silica nanoparticles targeted bladder cancer for a highly effective combination therapy. Front. Bioeng. Biotechnol. 10, 949704 (2022).
   PubMed Web of Science ®Google Scholar
• Xia Y, Xu T, Wang C et al. Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy. Int. J. Nanomed. 13, 143 (2018).
   PubMed Web of Science ®Google Scholar
• Gandin V, Khalkar P, Braude J, Fernandes AP. Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment. Free Radic. Biol. Med. 127, 80–97 (2018).
   PubMed Web of Science ®Google Scholar
• Collery P. Strategies for the development of selenium-based anticancer drugs. J. Trace Elem. Med. Biol. 50, 498–507 (2018).
   PubMed Web of Science ®Google Scholar
• Radomska D, Czarnomysy R, Radomski D, Bielawski K. Selenium compounds as novel potential anticancer agents. Int. J. Mol. Sci. 22(3), 1009 (2021).
   PubMed Web of Science ®Google Scholar
• Lin W, Zhang J, Xu J-F, Pi J. The advancing of selenium nanoparticles against infectious diseases. Front. Pharmacol. 12, 1971 (2021).
   Web of Science ®Google Scholar
• Guo M, Li Y, Lin Z et al. Surface decoration of selenium nanoparticles with curcumin induced HepG2 cell apoptosis through ROS mediated p53 and AKT signaling pathways. RSC Adv. 7(83), 52456–52464 (2017).
   Web of Science ®Google Scholar
• Li T, Xu H. Selenium-containing nanomaterials for cancer treatment. Cell Reports Phys. Sci. 1(7), 100111 (2020).
   Google Scholar
• Maiyo F, Singh M. Folate-targeted mRNA delivery using chitosan-functionalized selenium nanoparticles: potential in cancer immunotherapy. Pharmaceuticals 12(4), 164 (2019).
   Web of Science ®Google Scholar
• Shahidi M, Abazari O, Dayati P et al. Aptamer-functionalized chitosan-coated gold nanoparticle complex as a suitable targeted drug carrier for improved breast cancer treatment. Nanotechnol. Rev. 11(1), 2875–2890 (2022).
   Web of Science ®Google Scholar
• Xia Y, Lin Z, Li Y et al. Targeted delivery of siRNA using RGDfC-conjugated functionalized selenium nanoparticles for anticancer therapy. J. Mater. Chem. B 5(33), 6941–6952 (2017).
   PubMed Web of Science ®Google Scholar
• Shahidi M, Abazari O, Dayati P, Haghiralsadat BF, Oroojalian F, Tofighi D. Targeted delivery of 5-fluorouracil, miR-532-3p and si-KRAS to colorectal tumor using layer-by-layer liposomes. Front. Bioeng. Biotechnol. 10, 1013541 (2022).
   PubMed Web of Science ®Google Scholar
• Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Exp. Hematol. Oncol. 9(1), 1–14 (2020).
   PubMed Web of Science ®Google Scholar
• Zhou J-Y, Chen M, Ma L, Wang X, Chen Y-G, Liu S-L. Role of CD44high/CD133high HCT-116 cells in the tumorigenesis of colon cancer. Oncotarget 7(7), 7657 (2016).
   PubMedGoogle Scholar
• Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J. Hematol. Oncol. 11(1), 1–23 (2018).
   PubMedGoogle Scholar
• Diaz-Salmeron R, Michel J-P, Hadji H et al. Role of the interactions of soft hyaluronan nanomaterials with CD44 and supported bilayer membranes in the cellular uptake. Colloids Surf. B Biointerfaces 205, 111916 (2021).
   PubMed Web of Science ®Google Scholar
• Xia Y, Tang G, Chen Y et al. Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma. Bioact. Mater. 6(5), 1330–1340 (2021).
   PubMed Web of Science ®Google Scholar
• Kim J, Chang J-Y, Kim Y-Y, Kim M-J, Kho H-S. Effects of molecular weight of hyaluronic acid on its viscosity and enzymatic activities of lysozyme and peroxidase. Arch. Oral Biol. 89, 55–64 (2018).
   PubMed Web of Science ®Google Scholar
• Oroojalian F, Babaei M, Taghdisi SM, Abnous K, Ramezani M, Alibolandi M. Encapsulation of thermo-responsive gel in pH-sensitive polymersomes as dual-responsive smart carriers for controlled release of doxorubicin. J. Control. Rel. 288, 45–61 (2018).
   PubMed Web of Science ®Google Scholar
• Huang Y, Long B, Tang M et al. Bifunctional catalytic material: an ultrastable and high-performance surface defect CeO2 nanosheets for formaldehyde thermal oxidation and photocatalytic oxidation. Appl. Catal. B Environ. 181, 779–787 (2016).
   Web of Science ®Google Scholar
• Xia Y, Guo M, Xu T et al. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy. Int. J. Nanomed. 13, 1539 (2018).
   PubMed Web of Science ®Google Scholar
• Weng J, Han X, Liu K et al. CD44 3′-untranslated region functions as a competing endogenous RNA to enhance NK sensitivity of liver cancer stem cell by regulating ULBP2 expression. Int. J. Biol. Sci. 15(8), 1664 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang X, Huang Z, Wang J et al. Targeting feedforward loops formed by nuclear receptor RORγ and kinase PBK in mCRPC with hyperactive AR signaling. Cancers (Basel) 13(7), 1672 (2021).
   PubMed Web of Science ®Google Scholar
• Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal. Biochem. 236(2), 302–308 (1996).
   PubMed Web of Science ®Google Scholar
• Khodaverdi E, Hadizadeh F, Hoseini N et al. In-vitro and in-vivo evaluation of sustained-release buprenorphine using in-situ forming lipid-liquid crystal gels. Life Sci. 314, 121324 (2023).
   PubMed Web of Science ®Google Scholar
• Hirsch FR, McElhinny A, Stanforth D et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol. 12(2), 208–222 (2017).
   PubMed Web of Science ®Google Scholar
• Loo DT. In situ detection of apoptosis by the TUNEL assay: an overview of techniques. In: DNA Damage Detect. Situ, Ex Vivo, Vivo. Springer, NY, Dordrecht, Heidelberg, London, 682, 3–13 (2011).
   Google Scholar
• Abstiens K, Figueroa SM, Gregoritza M, Goepferich AM. Interaction of functionalized nanoparticles with serum proteins and its impact on colloidal stability and cargo leaching. Soft Matter 15(4), 709–720 (2019).
   PubMed Web of Science ®Google Scholar
• Menon S, Ks SD, Santhiya R, Rajeshkumar S, Kumar V. Selenium nanoparticles: a potent chemotherapeutic agent and an elucidation of its mechanism. Colloids Surf. B Biointerfaces 170, 280–292 (2018).
   PubMed Web of Science ®Google Scholar
• Iliaki S, Beyaert R, Afonina IS. Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochem. Pharmacol. 193, 114747 (2021).
   PubMed Web of Science ®Google Scholar
• Elsayed I, Wang X. PLK1 inhibition in cancer therapy: potentials and challenges. Future Med. Chem. 11(12), 1383–1386 (2019).
   PubMed Web of Science ®Google Scholar
• Dietrich P, Freese K, Mahli A, Thasler WE, Hellerbrand C, Bosserhoff AK. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic ‘dual-hit’ option. Oncotarget 9(3), 3605 (2018).
   PubMedGoogle Scholar
• Song R, Hou G, Yang J et al. Effects of PLK1 on proliferation, invasion and metastasis of gastric cancer cells through epithelial–mesenchymal transition. Oncol. Lett. 16(5), 5739–5744 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhang G, Kong C. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. In: Urologic Oncology: Seminars and Original Investigations. Elsevier, 1222–1230 (2013).
   Google Scholar
• de Cárcer G, Venkateswaran SV, Salgueiro L et al. Plk1 overexpression induces chromosomal instability and suppresses tumor development. Nat. Commun. 9(1), 1–14 (2018).
   PubMedGoogle Scholar
• Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA versus miRNA as therapeutics for gene silencing. Mol. Ther. Acids 4, e252 (2015).
   PubMedGoogle Scholar
• Zheng W, Yin T, Chen Q et al. Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers. Acta Biomater. 31, 197–210 (2016).
   PubMed Web of Science ®Google Scholar
• Pourpirali R, Mahmoudnezhad A, Oroojalian F, Zarghami N, Pilehvar Y. Prolonged proliferation and delayed senescence of the adipose-derived stem cells grown on the electrospun composite nanofiber co-encapsulated with TiO2 nanoparticles and metformin-loaded mesoporous silica nanoparticles. Int. J. Pharm. 604, 120733 (2021).
   PubMedGoogle Scholar
• Xia Y, Zhao M, Chen Y et al. Folate-targeted selenium nanoparticles deliver therapeutic siRNA to improve hepatocellular carcinoma therapy. RSC Adv. 8(46), 25932–25940 (2018).
   PubMed Web of Science ®Google Scholar
• Sheikhlou K, Allahyari S, Sabouri S, Najian Y, Jafarizadeh-Malmiri H. Walnut leaf extract-based green synthesis of selenium nanoparticles via microwave irradiation and their characteristics assessment. Open Agric. 5(1), 227–235 (2020).
   Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF et al. Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol. 16(1), 1–33 (2018).
   PubMed Web of Science ®Google Scholar
• Munir MU. Nanomedicine penetration to tumor: challenges, and advanced strategies to tackle this issue. Cancers (Basel) 14(12), 2904 (2022).
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 20(2), 101–124 (2021).
   PubMed Web of Science ®Google Scholar
• Pochapski DJ, Carvalho dos Santos C, Leite GW, Pulcinelli SH, Santilli CV. Zeta potential and colloidal stability predictions for inorganic nanoparticle dispersions: effects of experimental conditions and electrokinetic models on the interpretation of results. Langmuir 37(45), 13379–13389 (2021).
   PubMed Web of Science ®Google Scholar
• de Brito e Cunha D, Frederico ABT, Azamor T et al. Biotechnological evolution of siRNA molecules: from bench tool to the refined drug. Pharmaceuticals 15(5), 575 (2022).
   Web of Science ®Google Scholar
• Li S-R, Huo F-Y, Wang H-Q et al. Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy. J. Nanobiotechnol. 20(1), 1–19 (2022).
   PubMed Web of Science ®Google Scholar
• Goyal R, Chopra H, Dua K, Gautam RK. Insights on prospects of nano-siRNA based approaches in treatment of cancer. Front. Pharmacol. 13, 3502 (2022).
   Web of Science ®Google Scholar
• Naidoo S, Daniels A, Habib S, Singh M. Poly-l-lysine–lactobionic acid-capped selenium nanoparticles for liver-targeted gene delivery. Int. J. Mol. Sci. 23(3), 1492 (2022).
   PubMed Web of Science ®Google Scholar
• Cai J, Fu J, Li R, Zhang F, Ling G, Zhang P. A potential carrier for antitumor targeted delivery-hyaluronic acid nanoparticles. Carbohydr. Polym. 208, 356–364 (2019).
   PubMed Web of Science ®Google Scholar
• Mei H, Cai S, Huang D, Gao H, Cao J, He B. Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: from intrinsic physicochemical properties to external modification. Bioact. Mater. 8, 220–240 (2022).
   PubMed Web of Science ®Google Scholar
• Lian D, Chen Y, Xu G et al. Delivery of siRNA targeting HIF-1α loaded chitosan modified d-α-tocopheryl polyethylene glycol 1000 succinate-b-poly (ε-caprolactone-ran-glycolide) nanoparticles into nasopharyngeal carcinoma cell to improve the therapeutic efficacy of cisplatin. RSC Adv. 6(44), 37740–37749 (2016).
   Web of Science ®Google Scholar
• Johnson DE, Ostrowski P, Jaumouillé V, Grinstein S. The position of lysosomes within the cell determines their luminal pH. J. Cell Biol. 212(6), 677–692 (2016).
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17(2), 93–115 (2017).
   PubMed Web of Science ®Google Scholar
• Shahidi M, Moradi A, Dayati P. Zingerone attenuates zearalenone-induced steroidogenesis impairment and apoptosis in TM3 Leydig cell line. Toxicon 211, 50–60 (2022).
   PubMed Web of Science ®Google Scholar
• Colicino EG, Hehnly H. Regulating a key mitotic regulator, polo-like kinase 1 (PLK1). Cytoskeleton 75(11), 481–494 (2018).
   PubMed Web of Science ®Google Scholar
• Gheghiani L, Wang L, Zhang Y et al. PLK1 induces chromosomal instability and overrides cell-cycle checkpoints to drive tumorigenesis. Cancer Res. 81(5), 1293–1307 (2021).
   PubMed Web of Science ®Google Scholar
• Urbán P, Liptrott NJ, Bremer S. Overview of the blood compatibility of nanomedicines: a trend analysis of in vitro and in vivo studies. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 11(3), e1546 (2019).
   PubMed Web of Science ®Google Scholar
• de la Harpe KM, Kondiah PPD, Choonara YE, Marimuthu T, du Toit LC, Pillay V. The hemocompatibility of nanoparticles: a review of cell–nanoparticle interactions and hemostasis. Cells 8(10), 1209 (2019).
   PubMed Web of Science ®Google Scholar
• Edis Z, Wang J, Waqas MK, Ijaz M, Ijaz M. Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives. Int. J. Nanomed. 16, 1313 (2021).
   PubMed Web of Science ®Google Scholar